Clustering-Based Method for Developing a Genomic Copy Number Alteration Signature for Predicting the Metastatic Potential of Prostate Cancer.

The transition of cancer from a localized tumor to a distant metastasis is not well understood for prostate and many other cancers, partly, because of the scarcity of tumor samples, especially metastases, from cancer patients with long-term clinical follow-up. To overcome this limitation, we developed a semi-supervised clustering method using the tumor genomic DNA copy number alterations to classify each patient into inferred clinical outcome groups of metastatic potential. Our data set was comprised of 294 primary tumors and 49 metastases from 5 independent cohorts of prostate cancer patients. The alterations were modeled based on Darwin's evolutionary selection theory and the genes overlapping these altered genomic regions were used to develop a metastatic potential score for a prostate cancer primary tumor. The function of the proteins encoded by some of the predictor genes promote escape from anoikis, a pathway of apoptosis, deregulated in metastases. We evaluated the metastatic potential score with other clinical predictors available at diagnosis using a Cox proportional hazards model and show our proposed score was the only significant predictor of metastasis free survival. The metastasis gene signature and associated score could be applied directly to copy number alteration profiles from patient biopsies positive for prostate cancer.

[1]  M. Nagane,et al.  Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. , 2008, Neurosurgery.

[2]  N. Sunaga,et al.  l‐type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms , 2008, Cancer science.

[3]  C. Creighton,et al.  Genomic profiling of prostate cancers from African American men. , 2009, Neoplasia.

[4]  Zhifu Sun,et al.  A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer , 2006, PLoS medicine.

[5]  Y. Kanai,et al.  l‐Type amino acid transporter 1 inhibitors inhibit tumor cell growth , 2010, Cancer science.

[6]  Jin Woo Kim,et al.  DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies , 2007, The Prostate.

[7]  Jun Luo,et al.  Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.

[8]  Peter J. Park,et al.  Comparative analysis of algorithms for identifying amplifications and deletions in array CGH data , 2005, Bioinform..

[9]  Bert Vogelstein,et al.  Genetic instability and darwinian selection in tumours , 1999 .

[10]  Y. Kanai,et al.  BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. , 2008, Biological & pharmaceutical bulletin.

[11]  D. Ross,et al.  Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A novel five-antibody immunohistochemical test for subclassification of lung carcinoma , 2010 .

[13]  Jeffrey P. MacKeigan,et al.  Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy , 2009, Cell.

[14]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[15]  M. Kattan,et al.  Radical prostatectomy for carcinoma of the prostate , 2004, Modern Pathology.

[16]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[17]  Terence P. Speed,et al.  Genome analysis A genotype calling algorithm for affymetrix SNP arrays , 2005 .

[18]  Hans Christian Pedersen,et al.  Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy , 2010, Breast Cancer Research.

[19]  J. Cheville,et al.  Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer , 2009, Cancer investigation.

[20]  E. Bergstralh,et al.  Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. , 2007, The Journal of urology.

[21]  Gerhard Christofori,et al.  Mechanisms of Motility in Metastasizing Cells , 2010, Molecular Cancer Research.

[22]  J. Brooks,et al.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.

[23]  山内 宏一 System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line , 2009 .

[24]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[25]  Y. Kanai,et al.  System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. , 2009, Cancer letters.

[26]  Y. Kanai,et al.  L‐type amino‐acid transporter 1 as a novel biomarker for high‐grade malignancy in prostate cancer , 2009, Pathology international.

[27]  S. Saydam,et al.  Predicting invasive phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in primary breast cancer , 2009, Cancer science.

[28]  M. Djamgoz,et al.  Voltage‐gated K+ channel activity in human prostate cancer cell lines of markedly different metastatic potential: Distinguishing characteristics of PC‐3 and LNCaP cells , 2001, The Prostate.

[29]  Joshua M. Korn,et al.  Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs , 2008, Nature Genetics.

[30]  Ying Yu,et al.  Bcl-2 decreases voltage-gated K+ channel activity and enhances survival in vascular smooth muscle cells. , 2001, American journal of physiology. Cell physiology.

[31]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Y. Asmann,et al.  A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy , 2008, PloS one.

[33]  Y. Kanai,et al.  Properties of L-Type Amino Acid Transporter 1 in Epidermal Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.

[34]  N. Sunaga,et al.  L‐type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non‐small cell lung cancer , 2009, Histopathology.

[35]  H. Arakawa,et al.  Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. , 2010, Biochemical pharmacology.

[36]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.